Skip to content

US · SEER · BIOTECHNOLOGY

Seer, Inc. (SEER) intrinsic value and stock valuation

$1.36as of 2026-11-21 · Mkt cap 120.41M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Seer, Inc. DCF and intrinsic value

InvestorsCraft values SEER with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SEER’s statements →

Seer, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Redwood City, CA 94065 seer.bio

How the business is doing

Fiscal 2018–2025, USD

Revenue
$16.1M+89.5% 5y CAGRd
20182025
Net income
-$-73.6M
20182025
Free cash flow
-$-46.24M
20182025
Total equity
$259.3M-9.7% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$16.1M$14M$15.2M$14.7M$6.39M
Operating income-$-77.99M-$-100.1M-$-104.94M-$-98.04M-$-71.7M
Net income-$-73.6M-$-86.6M-$-86.28M-$-92.97M-$-71.17M
EPSd-$-1.28M-$-1.39M-$-1.35M-$-1.49M-$-1.17M
Operating cash flow-$-44.45M-$-46.11M-$-59.06M-$-60.78M-$-46.35M
Capital expenditure-$-1.8M-$-3.58M-$-7.31M-$-10.27M-$-6.92M
Free cash flow-$-46.24M-$-49.69M-$-66.37M-$-71.05M-$-53.27M
Total assets$296.1M$366.6M$436.3M$487.9M$539.1M
Total debt$23.7M$26M$28.3M$29.9M$23.3M
Net debt-$-23.63M-$-14.79M-$-4.24M-$-23.33M-$-209.49M
Total equity$259.3M$327.6M$396.9M$447M$502.9M
Cash and short-term investments$185.9M$236.4M$316.2M$421.2M$400.1M
Income statement
20252024202320222021
Revenue$16.1M$14M$15.2M$14.7M$6.39M
Cost of revenue$8.11M$7.12M$13.7M$14.3M$6.77M
Gross profit$8.01M$6.83M$1.45M$380K-$-370K
Research and development expenses$43.9M$50.6M$47.4M$45.8M$29.1M
Selling, general and administrative expenses$42.6M$56.6M$59M$52.6M$42.2M
Other expenses-$-460K-$-220K$0.00$0.00$0.00
Operating expenses$86M$106.9M$106.4M$98.4M$71.3M
Cost and expenses$94.1M$114.1M$120.1M$112.7M$78.1M
Interest income$11.5M$16.7M$17.8M$4.6M$330K
Interest expense$0.00$0.00$0.00$0.00$20K
Depreciation and amortization$6.1M$6.18M$5.58M$5.9M$3.56M
Ebitda-$-71.89M-$-80.33M-$-80.7M-$-87.06M-$-67.61M
Operating income-$-77.99M-$-100.1M-$-104.94M-$-98.04M-$-71.7M
Total other income/expenses, net$4.59M$13.6M$18.7M$5.08M$530K
Income before tax-$-73.4M-$-86.5M-$-86.28M-$-92.97M-$-71.17M
Income tax expense$200K$100K$0.00$0.00$0.00
Net income-$-73.6M-$-86.6M-$-86.28M-$-92.97M-$-71.17M
Weighted average shares outstanding$57.5M$62.4M$63.9M$62.4M$60.9M
Weighted average diluted shares outstanding$57.5M$62.4M$63.9M$62.4M$60.9M
Balance sheet
20252024202320222021
Cash and short-term investments$185.9M$236.4M$316.2M$421.2M$400.1M
Net receivables$5.95M$6.23M$6.72M$7.02M$4.14M
Inventory$7.79M$7.44M$4.49M$4.63M$4.14M
Total current assets$201.5M$253.3M$330.5M$435M$411.7M
Property, plant and equipment, net$35.2M$41.4M$47.4M$46.4M$33.2M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$54.7M$63.1M$56.9M$5.16M$93.2M
Total non-current assets$94.6M$113.3M$105.8M$53M$127.4M
Total assets$296.1M$366.6M$436.3M$487.9M$539.1M
Accounts payable$5.61M$4.62M$1.37M$2.1M$3.79M
Short-term debt$2.58M$2.31M$2.29M$1.84M$860K
Deferred revenue$340K$410K$210K$130K$380K
Total current liabilities$15.7M$15.3M$13.2M$12.6M$13.4M
Long-term debt$21.1M$23.7M$26M$28M$22.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$21.1M$23.7M$26.1M$28.4M$22.8M
Capital lease obligations$2.58M$23.7M$26M$29.9M$23.3M
Total liabilities$36.8M$39M$39.4M$40.9M$36.2M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-465.97M-$-392.37M-$-305.77M-$-219.5M-$-126.53M
Accumulated other comprehensive income (loss)$460K$140K-$-190K-$-1.25M-$-540K
Total equity$259.3M$327.6M$396.9M$447M$502.9M
Total investments$193.3M$258.8M$340.6M$373.2M$260.5M
Total debt$23.7M$26M$28.3M$29.9M$23.3M
Net debt-$-23.63M-$-14.79M-$-4.24M-$-23.33M-$-209.49M
Cash flow statement
20252024202320222021
Net income-$-73.6M-$-86.6M-$-86.28M-$-92.97M-$-71.17M
Depreciation and amortization$7.25M$6.18M$5.58M$3.94M$2.56M
Stock-based compensation$15.4M$28.2M$34.4M$33.7M$25.9M
Change in working capital-$-580K-$-140K-$-2.72M-$-7.09M-$-5.87M
Accounts receivable$280K$490K$300K-$-2.87M-$-2.5M
Inventory-$-2.9M-$-2.67M-$-1.95M-$-1.59M-$-3.59M
Accounts payable$1.06M$3.35M-$-990K-$-1.55M$1.6M
Net cash provided by operating activities-$-44.45M-$-46.11M-$-59.06M-$-60.78M-$-46.35M
Investments in property, plant and equipment-$-1.8M-$-3.58M-$-7.31M-$-10.27M-$-6.92M
Acquisitions, net$0.00$0.00$0.00$0.00$164M
Net cash used for investing activities$61.6M$65.9M$37.9M-$-122.72M-$-170.88M
Common stock issued$460K$0.00$0.00$0.00$103M
Common stock repurchased-$-10.2M-$-11.82M-$-10K-$-20K-$-40K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-10.57M-$-11.49M$450K$3.89M$116.6M
Net change in cash$6.53M$8.25M-$-20.71M-$-179.6M-$-100.59M
Cash at end of period$47.8M$41.3M$33M$53.7M$233.3M
Operating cash flow-$-44.45M-$-46.11M-$-59.06M-$-60.78M-$-46.35M
Capital expenditure-$-1.8M-$-3.58M-$-7.31M-$-10.27M-$-6.92M
Free cash flow-$-46.24M-$-49.69M-$-66.37M-$-71.05M-$-53.27M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Seer, Inc.

        Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.

        CEO
        Omid C. Farokhzad
        Employees
        124
        Beta
        1.59

        Explore

        Frequently asked questions

        What is the intrinsic value of Seer, Inc. (SEER)?

        Seer, Inc. (SEER) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SEER undervalued?

        SEER trades at a price of $1.36 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.